慢性肾病患者胸主动脉腔内修复术后的结局:Medicare人群分析
该研究基于2000至2014年Medicare数据库,纳入27079例接受胸主动脉腔内修复术的患者,按肾功能分层比较术后生存和并发症。结果显示,慢性肾病III期、IV期及终末期肾病/血液透析患者生存显著更差,脓毒症风险增加,提示对此类患者应更谨慎评估手术获益与风险。
要点
- 慢性肾病III期、IV期及终末期肾病/透析患者胸主动脉腔内修复术后生存显著低于肾功能正常者。
- 慢性肾病III期、IV期及终末期肾病/透析患者术后30天脓毒症风险显著增加。
- 慢性肾病I/II期与无慢性肾病患者的死亡风险无显著差异。
核心结论
- 在老年Medicare人群中,慢性肾病III期、IV期或终末期肾病/血液透析患者接受胸主动脉腔内修复术后生存差且并发症增加。
- 数据提示对慢性肾病III期、IV期或终末期肾病/血液透析患者应更谨慎评估胸主动脉腔内修复术,权衡手术获益与高预期死亡率。
研究设计与样本
- 回顾性队列研究,基于2000至2014年Medicare按服务收费数据库,纳入27079例接受胸主动脉腔内修复术的患者。
- 按肾功能分层:无慢性肾病23375例(86%),慢性肾病I/IV期2957例(11%),终末期肾病或血液透析747例(3%)。
- 比较调整后全因死亡率和术后并发症发生率。
主要发现
- 总生存率随慢性肾病分期加重而显著下降:无慢性肾病1年生存率78%,慢性肾病I/II期77%,慢性肾病III期67%,慢性肾病IV期58%,终末期肾病或血液透析48%(P < .001)。
- 慢性肾病III期死亡风险比1.29(P < .001),慢性肾病IV期风险比1.74(P < .001),终末期肾病或血液透析风险比2.03(P < .001)。
- 无慢性肾病与慢性肾病I/II期患者之间无死亡风险差异。
- 术后30天脓毒症风险:慢性肾病III/IV期风险比1.7(P < .001),终末期肾病或血液透析风险比2.7(P < .001)。
临床怎么用
- 对慢性肾病III期、IV期或终末期肾病/血液透析患者,术前应充分评估胸主动脉腔内修复术的获益与高死亡风险。
- 术后应加强感染监测,尤其是脓毒症的早期识别与防治。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Thoracic endovascular aortic repair has been increasingly performed in higher-risk patients with renal failure. The objective was to compare Medicare patients with preoperative chronic kidney disease with patients with normal renal function to determine differences in postoperative survival and complications. METHODS: From 2000 to 2014, 27,079 Medicare fee-for service patients underwent thoracic endovascular aortic repair. Patients were stratified by kidney function, and 23,375 patients (86%) had no chronic kidney disease, 2957 patients (11%) had chronic kidney disease stage I/IV, and 747 patients (3%) had end-stage renal disease or hemodialysis. Groups were then compared with determined differences in adjusted all-cause mortality and rates of postoperative complications. RESULTS: Overall survival was significantly worse among patients with chronic kidney disease and end-stage renal disease or hemodialysis compared with patients with no chronic kidney disease (1-year survival no chronic kidney disease: 78%; chronic kidney disease I/II: 77%; chronic kidney disease III: 67%; chronic kidney disease IV: 58%; and end-stage renal disease or hemodialysis: 48%, P < .001). Mortality was significantly increased among patients with chronic kidney disease III (hazard ratio [HR], 1.29; P < .001), chronic kidney disease IV (HR, 1.74; P < .001), and end-stage renal disease or hemodialysis (HR, 2.03; P < .001). No mortality difference was found between patients with no chronic kidney disease and patients with chronic kidney disease stage I/II. At 30 days after thoracic endovascular aortic repair, sepsis was increased for patients with chronic kidney disease stage III/IV (HR, 1.7; P < .001) and end-stage renal disease or hemodialysis (HR, 2.7; P < .001). CONCLUSIONS: In this elderly Medicare population undergoing thoracic endovascular aortic repair, patients with chronic kidney disease stage III, chronic kidney disease stage IV, or end-stage renal disease/hemodialysis had poor survival and increased morbidity compared with those with normal kidney function. These data may suggest that patients with chronic kidney disease stage III, chronic kidney disease stage IV, or end-stage renal disease/hemodialysis should be more cautiously evaluated for thoracic endovascular aortic repair, weighing the benefits of the procedure against the high expected mortality.
引用
- Brown CR, Chen Z, Khurshan F, et al. Outcomes after thoracic endovascular aortic repair in patients with chronic kidney disease in the Medicare population. J Thorac Cardiovasc Surg. 2019. PMID: 30955964. doi:10.1016/j.jtcvs.2019.01.118
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。